Lipoprotein‐Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease oleh Lars Wallentin, Claes Held, Paul W. Armstrong, Christopher P. Cannon, Richard Y. Davies, Christopher B. Granger, Emil Hagström, Robert A. Harrington, Judith S. Hochman, Wolfgang Koenig, Sue Krug‐Gourley, Emile R. Mohler, Agneta Siegbahn, Elizabeth Tarka, Philippe Gabriel Steg, Ralph A. H. Stewart, Robert Weiss, Ollie Östlund, Harvey D. White, Andrzej Budaj, Diego Ardissino, Alvaro Avezum, Philip E. Aylward, Alfonso Bryce, Hong Chen, Ming‐Fong Chen, Ramon Corbalan, Anthony J. Dalby, Nicolas Danchin, Robbert J. De Winter, Stefan Denchev, Rafael Diaz, Moses Elisaf, Marcus D. Flather, Assen R. Goudev, Liliana Grinfeld, Steen Husted, Hyo‐Soo Kim, Ales Linhart, Eva Lonn, José López‐Sendón, Athanasios J. Manolis, José C. Nicolau, Prem Pais, Alexander Parkhomenko, Terje R. Pedersen, Daniel Pella, Marco A. Ramos‐Corrales, Mikhail Ruda, Mátyás Sereg, Saulat Siddique, Peter Sinnaeve, Piyamitr Sritara, Henk P. Swart, Rody G. Sy, Tamio Teramoto, Hung‐Fat Tse, W. Douglas Weaver, Margus Viigimaa, Dragos Vinereanu, Junren Zhu